Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approach

por Overgaard, Rune V., Lindberg, Søren Ø., Thielke, Desirée
Publicado 2018

Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes

por Buse, John B., Holst, Ingrid, Knop, Filip K., Kvist, Kajsa, Thielke, Desirée, Pratley, Richard
Publicado 2021

Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden

por Andersson, Emelie, Persson, Sofie, Hallén, Nino, Ericsson, Åsa, Thielke, Desirée, Lindgren, Peter, Steen Carlsson, Katarina, Jendle, Johan
Publicado 2020

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

por McCrimmon, Rory J., Catarig, Andrei-Mircea, Frias, Juan P., Lausvig, Nanna L., le Roux, Carel W., Thielke, Desirée, Lingvay, Ildiko
Publicado 2020